Childhood B-Lymphoblastic Leukemia Treatment Study

Clinical Trial Title

Risk-stratified randomized phase III testing of blinatumomab (IND# I17467, NSC# 765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL).

Contact Information

Nitin Sane

Clinical Trial Protocol Description:

AALL 1331 is a group wide risk-stratified, randomized phase III study to test whether incorporation of blinatumomab into the treatment of patients with childhood B-lymphoblastic leukemia (B-ALL) at first relapse will improve disease free survival. Blinatumomab is being tested in this population based on its demonstrated safety profile and single agent activity (induction of MRD-negative remissions in children with multiple relapsed refractory B-ALL).

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between one year of age and 31 years of age at the time of relapse.
  • Have had first relapse of B-ALL. Allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Nitin Sane

(312) 355-0741

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more